Podcast Index
Explora podcasts por categoría, abre episodios recientes y descarga audio para escucharlo sin conexión.
BioCentury This Week
BioCentury
The Environmental Justice Lab
Lesley Joseph
TheThinkingAtheist
The Thinking Atheist
Rachel Lawson's The Magicians Podcast
Rachel Lawson
AI News Podcast | Latest AI News, Analysis & Events | Daily Inference
AI Daily
That UFO Podcast
That UFO Podcast
Thrilling Threads - Conspiracy Theories, Strange Phenomena, True Crime, Unsolved Mysteries, etc!
Byte & Pieces
Astronomy Daily: Space News Updates
bitesz.com
DayWeather Podcast
DayWeather
Small Nonprofit: Fundraising Tips, Leadership Strategies, and Community-Centric Solutions
Further Together: Fundraising Strategies for Nonprofit Organizations
The Grave Talks | Haunted, Paranormal & Supernatural
Ghost Stores, Haunted, Paranormal & Supernatural Stories
Emergence Magazine Podcast
Emergence Magazine
Welcome to Florida
Chadd Scott
Real Ghost Stories Online
Real Ghost Stories Online | Paranormal, Supernatural & Horror Radio
Cotton Specialists Corner
Extension Cotton Specialists
Los Angeles Weather Daily
Fast Foundations
Phoenix Weather Daily
Fast Foundations
Fins, Fur, and Feathers
Joe Gerken and Drew Ricketts
San Diego Weather Daily
Fast Foundations
Psychotherapy and Applied Psychology
Dr. Daniel W Cox
San Francisco Weather Daily
Fast Foundations
Animals, Nature, and You
Rick Schwartz
The Pools Scientific Podcast
John Cooper
The Poultry Podcast Show
Wisenetix
Artificial Intelligence Masterclass
AI Masterclass
Quazi Johir
Quazi Johir
The Dirt on Gardening
Andre Baptiste, Graylen Brown, Derek Haynes
Stuck Not Broken
Justin Sunseri
The Parkinson's Podcast
Davis Phinney Foundation
Biophilic Solutions: Nature Has the Answers
Serenbe Media Network
What it Means To Be Human
Dan Zetterstrom / Double Barrel
The Global Grit Experience
Erika Gilsdorf
Are We Doomed?
NPR Network
Huberman Lab
Huberman Lab
Astronomie : Fragments d'Univers
Astronomie : Fragments d'Univers
Dateable: Your insider's look into modern dating and relationships
Yue Xu and Julie Krafchick
A Better Way To Farm Podcast
Rod Livesay
Ciencia
BioCentury
New Parkinson’s disease programs aim to move beyond the historical norm of symptom management, branching into targeted therapeutics and cell therapies. On the latest BioCentury This Week podcast, BioCentury’s analysts re...
AbbVie's $10.9 billion deal to acquire Apogee will expand its immunology pipeline by delivering assets for atopic dermatitis and asthma. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the takeo...
Biotech IPOs that are getting out remain hot — but will that continue into the fall? On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the market for fresh biotech paper on NASDAQ, including the $...
Getting into the clinic fast to de-risk assets has become the name of the game in biotech, and at the academia-industry interface, too.From AI to NAMs to starting a Phase I trial in the U.S., BioCentury’s 3rd Grand Round...
FDA’s new leadership is sailing the agency into calmer waters amid a search for a permanent commissioner and permanent center directors. On the latest BioCentury This Week podcast, BioCentury Washington Editor Steve Usdi...
Revolution Medicines continues to impress with more pancreatic cancer data, earning a standing ovation at ASCO over the weekend. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the detailed data...
At ASCO among presentations focused on pancreatic cancer innovation beyond KRAS; however, abstracts for the cancer conference also highlight ADCs, bispecifics and diagnostics that are broadening the field’s approach to t...
Marty Makary wasn’t the only official on the outs at FDA last week in another tumultuous turn of events for the regulatory agency. On the latest BioCentury This Week podcast, BioCentury Washington Editor Steve Usdin disc...
China’s speed in generating first-in-human data has catalyzed a race across the globe to reshape regulatory requirements to compete. BioCentury’s analysts, along with special guests Detlev Mennerich, head of Boehringer I...
Marty Makary’s hold on the top job at FDA is slipping, with White House leaks about President Donald Trump’s displeasure with the FDA commissioner shifting the question from whether he will be fired to when. On the lates...
UCB is the latest biopharma player to consummate a multibillion-dollar deal amid a surge in biotech M&A activity, acquiring Ken Song’s Candid Therapeutics, one of the leading T cell engager companies. On the latest BioCe...
More than 175 new oncology targets surfaced at this year’s American Association for Cancer Research annual meeting in San Diego, with the focus on new ways to enhance the immune response against solid tumors and to make ...
Bispecific antibodies and dual-payload antibody-drug conjugates were in the spotlight at this year’s American Association for Cancer Research meeting in San Diego as biotechs unveiled their latest preclinical and first-i...
The past week has delivered the largest M&A deal ever for a private, venture-backed biopharma, the second-largest follow-on ever for a NASDAQ-traded biotech and what could soon become the largest biotech IPO ever on NASD...
A pathway proposed by FDA to cut the time it takes biopharma companies to get to first-in-human trials is more ambitious than similar policies in Australia, China and the U.K. On the latest BioCentury This Week podcast, ...
Biotech has been resilient as the financial markets teeter under global volatility. For now, M&A and financings, if not IPOs, are continuing, but will the Mideast conflict halt biotech’s recovery? On the latest BioCentur...
Biotech innovators around the world are finding speed to be the driver for investment and partnering — speed to early human data and speed to de-risk assets. The new momentum from Asia, in particular China, has added a f...
A flurry of deals, several with sizable upfront payments, has energized the biotech sector in March. On the latest BioCentury This Week podcast, BioCentury’s Paul Bonanos assesses last week’s deals by Merck, which is lay...
After 20 years of platform building and resets, Arrowhead Pharmaceuticals is making a bid to become a large-cap biotech. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss how the company has built...
Biotechs have been pricing follow-ons at a steady pace, with some companies parlaying data into upsized deals, and others even beginning to debut on NASDAQ — but will geopolitical tensions and war in the Middle East scut...
Completa el formulario de abajo. Asegúrate de seleccionar tanto País como Géneros.
Envíanos un mensaje abajo. Te responderemos en un plazo de 24 horas.